Primary Myelofibrosis Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)

Primary Myelofibrosis Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)

DelveInsight’s, “Primary Myelofibrosis Pipeline Insight, 2023” report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in the Primary Myelofibrosis pipeline landscape. It covers the Primary Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Primary Myelofibrosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Primary Myelofibrosis Pipeline Report

  • DelveInsight’s Primary Myelofibrosis pipeline report depicts a robust space with 55+ active players working to develop 55+ pipeline therapies for Primary Myelofibrosis treatment.
  • The leading companies working in the Primary Myelofibrosis Market include Nippon Shinyaku, Kartos Therapeutics, Sumitomo Pharma Oncology, Incyte Corporation, Novartis, Keros Therapeutics Inc., IQVIA Biotech, CTI BioPharma, PSI CRO, Celgene, Parexel, Pharmaxis, NS Pharma Inc., Nippon Shinyaku Co. Ltd., Bristol-Myers Squibb, AbbVie, Telios Pharma Inc., Sanofi, and others.
  • Promising Primary Myelofibrosis Pipeline Therapies in the various stages of development include Ruxolitinib, KER-050 monotherapy, Pacritinib, FEDRATINIB, PXS-5505, NS-018, APLIDIN (plitidepsin), and others.
  • September 2023: Bristol-Myers Squibb announced a study of Phase 1 & 2 Clinical trials for BMS-986158, Ruxolitinib, and Fedratinib. The purpose of this study is to assess the safety, tolerability, and efficacy of BMS-986158 alone and in combination with either Ruxolitinib or Fedratinib in participants with Dynamic International Prognostic Scoring System (DIPSS)-intermediate or high risk blood cancer.
  • September 2023: Karyopharm Therapeutics Inc. announced a study of Phase 3 Clinical Trials for Selinexor and Ruxolitinib. This is a global, multicenter Phase 1/3 study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended dose (RD) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a) and a dose expansion part (Phase 1b). In Phase 3, JAKi treatment-naïve MF participants are enrolled in 2:1 ratio to receive the combination therapy of selinexor + ruxolitinib or the combination of placebo + ruxolitinib.

 

Request a sample and discover the recent advances in Primary Myelofibrosis Treatment Drugs @ Primary Myelofibrosis Pipeline Report

 

In the Primary Myelofibrosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Primary Myelofibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Primary Myelofibrosis Overview

Primary myelofibrosis (also called chronic idiopathic myelofibrosis, agnogenic myeloid metaplasia) is a disorder in which normal bone marrow tissue is gradually replaced with a fibrous scar-like material. Over time, this leads to progressive bone marrow failure. Under normal conditions, the bone marrow provides a fine network of fibres on which the stem cells can divide and grow.

 

Find out more about Primary Myelofibrosis Therapeutics Assessment @ Primary Myelofibrosis Preclinical and Discovery Stage Products

 

Primary Myelofibrosis Emerging Drugs Profile

  • NS 018: Nippon Shinyaku
  • KRT-232: Kartos Therapeutics
  • TP 3654: Sumitomo Pharma Oncology

 

Primary Myelofibrosis Pipeline Therapeutics Assessment

There are approx. 55+ key companies which are developing the Primary Myelofibrosis therapies. The Primary Myelofibrosis companies which have their Primary Myelofibrosis drug candidates in the most advanced stage, i.e. Phase II/III include, Kartos Therapeutics.

 

Learn more about the emerging Primary Myelofibrosis Pipeline Therapies @ Primary Myelofibrosis Clinical Trials Assessment

 

Scope of the Primary Myelofibrosis Pipeline Report

  • Coverage- Global
  • Primary Myelofibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Primary Myelofibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Primary Myelofibrosis Companies- Nippon Shinyaku, Kartos Therapeutics, Sumitomo Pharma Oncology, Incyte Corporation, Novartis, Keros Therapeutics Inc., IQVIA Biotech, CTI BioPharma, PSI CRO, Celgene, Parexel, Pharmaxis, NS Pharma Inc., Nippon Shinyaku Co. Ltd., Bristol-Myers Squibb, AbbVie, Telios Pharma Inc., Sanofi, and others.
  • Primary Myelofibrosis Pipeline Therapies- Ruxolitinib, KER-050 monotherapy, Pacritinib, FEDRATINIB, PXS-5505, NS-018, APLIDIN (plitidepsin), and others.

 

Dive deep into rich insights for new drugs for Primary Myelofibrosis Treatment, Visit @ Primary Myelofibrosis Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Primary myelofibrosis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Primary myelofibrosis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase II/III)
  8. KRT-232: Kartos Therapeutics
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. NS 018: Nippon Shinyaku
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug name : Company name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name : Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Primary myelofibrosis Key Companies
  21. Primary myelofibrosis Key Products
  22. Primary myelofibrosis- Unmet Needs
  23. Primary myelofibrosis- Market Drivers and Barriers
  24. Primary myelofibrosis- Future Perspectives and Conclusion
  25. Primary myelofibrosis Analyst Views
  26. Primary myelofibrosis Key Companies
  27. Appendix

 

For further information on the Primary Myelofibrosis Pipeline therapeutics, reach out to Primary Myelofibrosis Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking